A new parameter in multiple myeloma: CYP3A4*1B single nucleotide polymorphism.

ABSTRACT: Multiple myeloma (MM) is a disease caused by malignant plasma cells, causing free light chain release accompanying the increase in monoclonal immunoglobulin. Cytochrome P450 (CYP) is one of the large and functional enzyme families composed of various hemoproteins. This protein network has been shown to play a role in many treatment steps in current practices. We aimed to investigate the relationship between genotypes of CYP3A4*1B and treatment response and prognosis of MM. Seventy-two patients diagnosed with MM between January 2016 and 2020 and 100 healthy people to create a control group participated in our study. Genotypes were classified in 3 separate groups as NN, MN, and MM. Both PFS and OS were significantly higher in the NN genotype (p?=?0.001, p?=?0.014). Being under the age of 65 was 27.988 times more protective for OS and 4.496 times for PFS (p?=?0.006, p?=?0.017). NN genotype was shown to be 41.666-fold protective for OS and 3.144-fold protective for PFS (p?=?0.004, p?=?0.030). This study demonstrated that CYP3A4*1B NN genotype, which is an important cytochrome p450 member for the treatment of MM, was 41.666-fold protective for OS and 3.144-fold protective for PFS. It was shown in this study for the first time in the literature as a valuable contribution.

SUBMITTER: Serin I 

PROVIDER: S-EPMC7653211 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature